Ligands of Immunopharmacology

Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist ( EC 50 =3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production

AVE3085 is a potent endothelial nitric oxide synthase enhancer, used for cardiovascular disease treatment.In VitroPre-incubation with AVE3085 restores the bradykinin-induced relaxation, reverses the decrease of p-eNOS Ser1177 , and loares the level

AVE3085 is a potent endothelial nitric oxide synthase enhancer, used for cardiovascular disease treatment.In VitroPre-incubation with AVE3085 restores the bradykinin-induced relaxation, reverses the decrease of p-eNOS Ser1177 , and loares the level

AVE3085 is a potent endothelial nitric oxide synthase enhancer, used for cardiovascular disease treatment.In VitroPre-incubation with AVE3085 restores the bradykinin-induced relaxation, reverses the decrease of p-eNOS Ser1177 , and loares the level

AVE3085 is a potent endothelial nitric oxide synthase enhancer, used for cardiovascular disease treatment.In VitroPre-incubation with AVE3085 restores the bradykinin-induced relaxation, reverses the decrease of p-eNOS Ser1177 , and loares the level

AVE3085 is a potent endothelial nitric oxide synthase enhancer, used for cardiovascular disease treatment.In VitroPre-incubation with AVE3085 restores the bradykinin-induced relaxation, reverses the decrease of p-eNOS Ser1177 , and loares the level

AVE3085 is a potent endothelial nitric oxide synthase enhancer, used for cardiovascular disease treatment.In VitroPre-incubation with AVE3085 restores the bradykinin-induced relaxation, reverses the decrease of p-eNOS Ser1177 , and loares the level

AVE3085 is a potent endothelial nitric oxide synthase enhancer, used for cardiovascular disease treatment.In VitroPre-incubation with AVE3085 restores the bradykinin-induced relaxation, reverses the decrease of p-eNOS Ser1177 , and loares the level

AXC-715 (T785) trihydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1 AXC-715 trihydrochloride, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody

AXC-715 (T785) trihydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1 AXC-715 trihydrochloride, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody

AXC-715 (T785) trihydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1 AXC-715 trihydrochloride, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody

AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC 50 values of 0.005 μM and 0.023 μM, respectively.